Cargando…

Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy

We evaluated the efficacy of percutaneous ethanol injection therapy (PEIT) as a therapeutic option for recurrence of secondary hyperparathyroidism after subtotal parathyroidectomy in ESRD patients. Six patients underwent PEIT. A mean of 1.3 ± 0.8 ethanol injections was performed. Nodular volume was...

Descripción completa

Detalles Bibliográficos
Autores principales: Douthat, Walter G., Cardozo, Gabriela, Garay, Gabriela, Orozco, Santiago, Chiurchiu, Carlos, de la Fuente, Jorge, de Arteaga, Javier, Massari, Pablo U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118542/
https://www.ncbi.nlm.nih.gov/pubmed/21716690
http://dx.doi.org/10.4061/2011/246734
_version_ 1782206487618125824
author Douthat, Walter G.
Cardozo, Gabriela
Garay, Gabriela
Orozco, Santiago
Chiurchiu, Carlos
de la Fuente, Jorge
de Arteaga, Javier
Massari, Pablo U.
author_facet Douthat, Walter G.
Cardozo, Gabriela
Garay, Gabriela
Orozco, Santiago
Chiurchiu, Carlos
de la Fuente, Jorge
de Arteaga, Javier
Massari, Pablo U.
author_sort Douthat, Walter G.
collection PubMed
description We evaluated the efficacy of percutaneous ethanol injection therapy (PEIT) as a therapeutic option for recurrence of secondary hyperparathyroidism after subtotal parathyroidectomy in ESRD patients. Six patients underwent PEIT. A mean of 1.3 ± 0.8 ethanol injections was performed. Nodular volume was 1.5 ± 1.7 cm(3), and 2.8 ± 2.8 cm(3) of ethanol was injected per patient. After ethanol injection PTH decreased significantly (1897 ± 754 to 549 ± 863 pg/mL (P < .01)). There was also a reduction in serum calcium, phosphorus and calcium-phosphorus product. A positive and significant correlation was found between nodular volume with ethanol injected and time from parathyroidectomy. Only one patient required hospitalization due to severe hypocalcaemia. In other two cases, local discomfort and temporary mild dysphonia were registered. PEIT is an effective treatment to control recurrences of secondary hyperparathyroidism postsubtotal parathyroidectomy.
format Online
Article
Text
id pubmed-3118542
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-31185422011-06-28 Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy Douthat, Walter G. Cardozo, Gabriela Garay, Gabriela Orozco, Santiago Chiurchiu, Carlos de la Fuente, Jorge de Arteaga, Javier Massari, Pablo U. Int J Nephrol Case Report We evaluated the efficacy of percutaneous ethanol injection therapy (PEIT) as a therapeutic option for recurrence of secondary hyperparathyroidism after subtotal parathyroidectomy in ESRD patients. Six patients underwent PEIT. A mean of 1.3 ± 0.8 ethanol injections was performed. Nodular volume was 1.5 ± 1.7 cm(3), and 2.8 ± 2.8 cm(3) of ethanol was injected per patient. After ethanol injection PTH decreased significantly (1897 ± 754 to 549 ± 863 pg/mL (P < .01)). There was also a reduction in serum calcium, phosphorus and calcium-phosphorus product. A positive and significant correlation was found between nodular volume with ethanol injected and time from parathyroidectomy. Only one patient required hospitalization due to severe hypocalcaemia. In other two cases, local discomfort and temporary mild dysphonia were registered. PEIT is an effective treatment to control recurrences of secondary hyperparathyroidism postsubtotal parathyroidectomy. SAGE-Hindawi Access to Research 2011-06-04 /pmc/articles/PMC3118542/ /pubmed/21716690 http://dx.doi.org/10.4061/2011/246734 Text en Copyright © 2011 Walter G. Douthat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Douthat, Walter G.
Cardozo, Gabriela
Garay, Gabriela
Orozco, Santiago
Chiurchiu, Carlos
de la Fuente, Jorge
de Arteaga, Javier
Massari, Pablo U.
Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
title Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
title_full Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
title_fullStr Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
title_full_unstemmed Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
title_short Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
title_sort use of percutaneous ethanol injection therapy for recurrent secondary hyperparathyroidism after subtotal parathyroidectomy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118542/
https://www.ncbi.nlm.nih.gov/pubmed/21716690
http://dx.doi.org/10.4061/2011/246734
work_keys_str_mv AT douthatwalterg useofpercutaneousethanolinjectiontherapyforrecurrentsecondaryhyperparathyroidismaftersubtotalparathyroidectomy
AT cardozogabriela useofpercutaneousethanolinjectiontherapyforrecurrentsecondaryhyperparathyroidismaftersubtotalparathyroidectomy
AT garaygabriela useofpercutaneousethanolinjectiontherapyforrecurrentsecondaryhyperparathyroidismaftersubtotalparathyroidectomy
AT orozcosantiago useofpercutaneousethanolinjectiontherapyforrecurrentsecondaryhyperparathyroidismaftersubtotalparathyroidectomy
AT chiurchiucarlos useofpercutaneousethanolinjectiontherapyforrecurrentsecondaryhyperparathyroidismaftersubtotalparathyroidectomy
AT delafuentejorge useofpercutaneousethanolinjectiontherapyforrecurrentsecondaryhyperparathyroidismaftersubtotalparathyroidectomy
AT dearteagajavier useofpercutaneousethanolinjectiontherapyforrecurrentsecondaryhyperparathyroidismaftersubtotalparathyroidectomy
AT massaripablou useofpercutaneousethanolinjectiontherapyforrecurrentsecondaryhyperparathyroidismaftersubtotalparathyroidectomy